肝细胞癌术后辅助治疗专家共识(2026版)OA

Recurrence and metastasis after surgery remain major determinants of long-term survival in patients with hepatocellular carcinoma(HCC),and to date,no universally accepted postoperative adjuvant therapy has been established to effectively prevent recurrence.In recent years,postoperative adjuvant strategies involving systemic antitumor therapies—represented by targeted agents and immune checkpoint inhibitors—used alone or in combination with locoregional therapies have been actively explored.The Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma,together with the Chinese College of Surgeons,the Committee of Liver Cancer of the Chinese Anti-Cancer Association,and the Liver Cancer Group of the Society of Oncology of the Chinese Medical Association,convened experts from relevant disciplines to review and synthesize updated evidence.Through multiple rounds of discussion and revision,the Expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2026 edition)was formulated.This consensus aims to systematically summarize the available evidence on postoperative adjuvant therapy for HCC,integrate current clinical practice,and provide practical guidance for clinicians,with the goal of improving postoperative survival outcomes in patients with HCC.